There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
A key pivotal study of bemarituzumab will read out shortly.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
A triplet did worse than control in first-line kidney cancer.
US approval could mark the company's graduation to oncology.
The FDA will rule on a low dose of zongertinib in the summer.
